Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

õ¸·»óºÎ ¾Ç¼º ½Å°æ±³Á¾¿¡¼­ ¼ö¼ú ÈÄ ¹æ»ç¼± Ä¡·áÀÇ ¿ªÇÒ -»ýÁ¸À²°ú ¿¹ÈÄÀÎÀÚ ºÐ¼®- Role of Postoperative Conventional Radiation Therapy in the Management of Supratentorial Malignant Glioma -with respect to survival outcome and prognostic factors-

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 1998³â 16±Ç 4È£ p.389 ~ 398
³²ÅñÙ, Á¤¿õ±â, ¾È¼ºÀÚ, ³ªº´½Ä,
¼Ò¼Ó »ó¼¼Á¤º¸
³²Åñ٠(  ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç

Á¤¿õ±â (  ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
¾È¼ºÀÚ (  ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç
³ªº´½Ä (  ) 
Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ¹æ»ç¼±Á¾¾çÇб³½Ç

Abstract

¸ñ Àû : õ¸·»óºÎ ¾Ç¼º ½Å°æ±³Á¾ÀÇ Ä¡·á·Î¼­ ¼ö¼ú ÈÄ ¹æ»ç¼± Ä¡·áÀÇ ¿ªÇÒÀ» »ýÁ¸À²À» Áß
½ÉÀ¸·Î Æò°¡ÇÏ¸ç ±× ¿¹ÈÄ ÀÎÀÚ¸¦ ºÐ¼®ÇÑ´Ù.
´ë»ó ¹× ¹æ¹ý : 1985³â 9¿ùºÎÅÍ 1997³â 3¿ù±îÁö ¼ö¼ú ÈÄ ¹æ»ç¼± Ä¡·á¸¦ ¹ÞÀº 69·ÊÀÇ È¯ÀÚ
¸¦ ´ë»óÀ¸·Î ºÐ¼®ÇÏ¿´°í ³ªÀÌÀÇ ¹üÀ§´Â 7¼¼¿¡¼­ 66¼¼À̸ç Áß¾Ó°£Àº 47¼¼¿´´Ù. 42·Ê(61%)´Â
´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾ À̾ú°í 27·Ê(39%)´Â ¾Ç¼º ¼º»ó¼¼Æ÷Á¾À̾ú´Ù. 20·Ê(29%)´Â Karnofsky ¿ª
ÇÒ¼öÇà ´É·Â Á¡¼ö°¡ 80Á¡ ÀÌ»óÀ̾ú´Ù. 43·Ê(62%)´Â ¼ö¼ú Àü 3°³¿ù À̳»¿¡ Áõ»óÀ» È£¼ÒÇÏ¿´
´Ù. 24·Ê(35%)´Â À°¾È »ó ¿ÏÀü ÀýÁ¦¸¦, 40·Ê(58%)´Â ºÎºÐ ÀýÁ¦¸¦, ³ª¸ÓÁö 5·Ê(7%)¿¡¼­´Â ³ú
Á¤À§ Á¶Á÷°Ë»ç¸¸ ½ÃÇàÇÏ¿´´Ù. ÃÑ ¹æ»ç¼± Á¶»ç·®Àº 50.4-61.2Gy(Áß¾Ó°ª, 55.8; ÃÖºó°ª, 59.4)·Î
ÇÏ·ç 1.8-2.0Gy ¾¿ 33-83ÀÏ µ¿¾È(Áß¾Ó°ª, 48) Ä¡·áÇÏ¿´´Ù. ´Ü 3·Ê´Â ¼ö¼ú ÈÄ Àü½Å »óÅÂÀÇ ºÒ
·®À¸·Î ÇÏ·ç 3.0Gy ¾¿ °¢°¢ 33, 36, 39Gy ±îÁö Ä¡·áÇÏ¿´´Ù. ÃßÀû °üÂûÀ²Àº 93%¿´°í Áß¾Ó°ª
Àº 14°³¿ùÀ̾ú´Ù.
°á °ú : Àüü ȯÀÚÀÇ 2³â ¹× 3³â »ýÁ¸À²°ú Áß¾Ó »ýÁ¸±â°£Àº °¢°¢ 38%, 20%, 16°³¿ùÀ̾ú
´Ù. ¾Ç¼º ¼º»ó¼¼Æ÷Á¾°ú ´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾ÀÇ Áß¾Ó»ýÁ¸±â°£Àº °¢°¢ 34, 14°³¿ùÀ̾ú´Ù
(p=0.0001).¿ÏÀüÀýÁ¦, ºÎºÐÀýÁ¦, ³úÁ¤À§ Á¶Á÷°Ë»ç±º¿¡¼­ÀÇ 3³â »ýÁ¸À²Àº °¢°¢ 38%, 11%, 0%
¿´´Ù(p=0.02). ¿¬·ÉÀÌ 40¼¼ ¹Ì¸¸, 40-59, 60¼¼ ÀÌ»ó ±ºÀÇ 3³â »ýÁ¸À²Àº °¢°¢ 52%, 8%, 0%¿´
´Ù(p=0.0007). ¿ªÇÒ ¼öÇà ´É·ÂÁ¡¼ö 80Á¡ ÀÌ»ó°ú 80Á¡ ¹Ì¸¸±ºÀÇ 3³â »ýÁ¸À²Àº °¢°¢ 53%, 9%
¿´´Ù(p=0.008). »ó±â¿Í °°ÀÌ ÀýÁ¦ Á¤µµ¿¡ µû¸¥ 3°³ÀÇ ¼ö¼ú ±º°ú 3°³ÀÇ ¿¬·É ±ºÀ» Æ÷ÇÔÇÑ ´Ù
¿äÀÎ ºÐ¼®¿¡¼­ º´¸®ÇÐÀû µî±Þ, ¼ö¼ú Á¤µµ, ¿¬·ÉÀÌ À¯ÀÇÇÑ ÀÎÀÚ¿´´Ù. ±×·¯³ª 2°³ÀÇ ¼ö¼ú ±º
(¿ÏÀü ÀýÁ¦¿Í ºñ¿ÏÀü ÀýÁ¦)°ú 2°³ÀÇ ¿¬·É ±º(50¼¼ ¹Ì¸¸°ú 50¼¼ ÀÌ»ó)À» °øº¯·®À¸·ÎÇÑ ´Ù¿ä
ÀÎ ºÐ¼®¿¡¼­ ¿¬·É´ë½Å º´¸®ÇÐÀû µî±Þ, ¼ö¼ú Á¤µµ, ¿ªÇÒ¼öÇà ´É·ÂÀÌ À¯ÀÇÇÑ ÀÎÀÚ¿´°í, À̵é
¼¼ °¡Áö ¿äÀÎÀ» °®Ãá 5·Ê´Â Ä¡·á¿Í °ü·ÃÇÑ ½É°¢ÇÑ ºÎÀÛ¿ë ¾øÀÌ 3³â ´©Àû»ýÁ¸À²ÀÌ 100%·Î
»ýÁ¸ÇÏ°í ÀÖ´Ù.
°á ·Ð : ¾Ç¼º ½Å°æ±³Á¾ÀÇ Ä¡·á¿¡¼­ ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á¸¦ Ãß°¡ÇÔÀ¸·Î½á ±âÁ¸ÀÇ ¼ö¼ú ´Üµ¶
ÀÇ »ýÁ¸À²À» Çâ»ó½ÃÅ°´Â ¿ªÇÒÀ» È®ÀÎÇÒ ¼ö ÀÖ¾ú´Ù. ¾Ç¼º ¼º»ó¼¼Æ÷Á¾ ȯÀÚ Áß, ƯÈ÷ ¾çÈ£ÇÑ
¿ªÇÒ¼öÇà ´É·Â°ú ¿ÏÀü ÀýÁ¦¸¦ ¹ÞÀº ȯÀÚ±ºÀÇ »ýÁ¸À²ÀÌ °¡Àå ¾çÈ£ÇÏ¿´´Ù. ´ÙÇü¼º ±³¸ð¼¼Æ÷Á¾
ȯÀÚ¿¡¼­´Â ƯÈ÷ ÀþÀº ³ªÀÌÀÎ °æ¿ì ÀûÀýÇÑ ½Å°æÇÐÀû ±â´Éº¸Á¸°ú ÇÔ²² ÃÖ´ëÇÑÀÇ Á¾¾ç ÀýÁ¦°¡
¼±ÇàµÇ¾î¾ß ÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù. ±×·¯³ª ¾çÈ£ÇÑ ¿¹ÈÄ ÀÎÀÚ¸¦ °®Áö ¸øÇÑ ´ëºÎºÐÀÇ ´ÙÇü¼º ±³
¸ð¼¼Æ÷Á¾ ȯÀÚ±ºÀÇ »ýÁ¸À²Àº ¿©ÀüÈ÷ ÁÁÁö ¾Ê¾Æ ÀÌ È¯ÀÚ ±º¿¡¼­´Â ¼ö¼ú ÈÄ Åë»óÀûÀÎ ¹æ»ç¼±
Ä¡·áº¸´Ù´Â ´Ù¸¥ Àû±ØÀûÀÎ Ä¡·á°¡ Ãß°¡ ¶Ç´Â ½ÃµµµÇ¾î¾ß ÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.

Purpose : To evaluate the role of conventional Postoperative adjuvant radiotherapy in
the management of supratentorial malignant glioma and to determine favorable
prognostic factors affecting survival.
Material and Methods : From Sep. 1985 to Mar. 1997. the number of eligible patients
who received postoperative radiotherapy completely was 69. They ranged in age from 7
to 66 years (median 47). Forty-two (61%) patients were glioblastoma multiforme and the
other 27 (39%) were anaplastic astrocytoma. Twenty patients (29%) had Karnofsky
score equal or more than 80 preoperatively. Forty-three patients (62%) had symptom
duration equal or less than 3 months. Twenty-four Patients (35%) had gross total
resection and forty patients(58%) had partial resection, the remaining five patients (7%)
had biopsy only. Radiotherapy dose ranged from 50.4 Gy to 61.2 Gy (median. 55.8: mode,
59.4) with fraction size of 1.8 Gy-2.0 Gy for 33-83 days(median. 48) except three
patients delivered 33. 36, 39 Gy, respectively with fraction size of 3.0 Gy due to poor
postoperative performance status. Follow-up rate was 93% and median follow-up period
was 14 months.
Results : Overall survival rate at 2 and 3 years and median survival were 38%, 20%,
and 16 months for entire patients: 67%, 44%, and 34 months for anaplastic astrocytoma:
18%, 4%, and 14 months for glioblastoma multiforme, respectively (p=0.0001). According
to the extent of surgery. 3-year overall survival for cross total resection, partial
resection, and biopsy only was 38%, 11%, and 0%, respectively (¥â=0.02). The 3-year
overall survival rates for patients age 40>, 40-59, and 60¡Â were 52%, 8%, and 0%
respectively (p=0.0007). For the variate of performance score 80¡Â vs 80>, the 3-year
survival rates were 53% and 9%, respectively (p=0.008). On multivariate analysis
including covariates of three surgical and age subgroups as above, pathology, extent of
surgery and age were significant prognostic factors affecting overall survival. On
another multivariate analysis with covariates of two surgical (total resection vs others)
and two age (50> vs 50¡Â) subgroups, then, pathology, extent of surgery and
performance status were significant factors instead of age and 3-year cumulative
survival rate for the five patients with these three favorable factors was 100% without
serious sequoia.
Conclusion : We confirmed the role of postoperative conventional radiotherapy in the
management of supratentorial malignant glioma by improving survival as compared with
historical data of surgery only. Patients with anaplastic astrocytoma, mood performance
score, gross total resection and/or young age survived longest. Maximum surgical
resection with acceptable preservation of neurologic function should be attempted in
glioblastoma patients, especially in younger patients. But the survival of most
glioblastoma patients without favorable factors is still poor, so other active adjuvant
treatment modalities should be tried or added rather than conventional radiation
treatment alone in this subgroup.

Å°¿öµå

Postoperative Radiation Therapy; Supratentorial Malignant Glioma;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS